CAS 379231-04-6
:Saracatinib
Description:
Saracatinib, with the CAS number 379231-04-6, is a small molecule inhibitor primarily known for its role as a selective inhibitor of the Src family of kinases. It is characterized by its ability to interfere with cellular signaling pathways that are often dysregulated in various cancers, making it a subject of interest in cancer research and therapy. Saracatinib has a molecular formula that reflects its complex structure, which includes multiple functional groups that contribute to its biological activity. The compound is typically administered orally and has been investigated in clinical trials for its efficacy in treating solid tumors and hematological malignancies. Its pharmacokinetic properties include moderate absorption and metabolism, with a focus on its safety profile and potential side effects. As a targeted therapy, Saracatinib exemplifies the trend towards personalized medicine in oncology, aiming to improve treatment outcomes by specifically inhibiting pathways critical for tumor growth and survival.
Formula:C27H32ClN5O5
InChI:InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
InChI key:InChIKey=OUKYUETWWIPKQR-UHFFFAOYSA-N
SMILES:N(C=1C=2C(OC3CCOCC3)=CC(OCCN4CCN(C)CC4)=CC2N=CN1)C5=C6C(=CC=C5Cl)OCO6
Synonyms:- 4-(6-Chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline
- 4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-
- 7-[2-[4-Methylpiperazin-1-yl]ethoxy]-5-[[tetrahydropyran-4-yl]oxy]-4-[[6-chloro-2,3-methylenedioxyphenyl]amino]quinazoline
- Azd 0530
- Azd 530
- Azd0530
- N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
- N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
CAS:Formula:C27H32ClN5O5Purity:99%Color and Shape:SolidMolecular weight:542.0265Saracatinib
CAS:Formula:C27H32ClN5O5Purity:>95.0%(HPLC)(qNMR)Color and Shape:White to Light yellow to Light orange powder to crystalMolecular weight:542.03Saracatinib
CAS:<p>Saracatinib (AZD0530) (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.</p>Formula:C27H32ClN5O5Purity:98% - 99.63%Color and Shape:SolidMolecular weight:542.03Saracatinib
CAS:<p>Inhibitor of Src and Abl tyrosine kinases; anti-proliferative; anti-migratory</p>Formula:C27H32ClN5O5Purity:Min. 95%Molecular weight:542.03 g/molN-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methyl-1-piperazinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-4-quinazolinamine
CAS:Purity:99% (HPLC)Molecular weight:542.0300293Saracatinib
CAS:Controlled Product<p>Applications An oral, selective dual inhibitor of Src and ABL kinase. It is a COVID19-related research product.<br>References Schweppe, R., et al.: J. Clin. Endocrinol., Metab., 94, 2199 (2009), Chen, Y., et al.: Clin. Canc. Res., 15, 3396 (2009), McDermott, U., et al.: Cancer Res., 70, 1625 (2010),<br></p>Formula:C27H32ClN5O5Color and Shape:NeatMolecular weight:542.03







